T-DXd is also approved for treatment in a new category of advanced breast cancer where HER2 expression is low (HER2-low) defined by either HER2 1+ or 2+ testing by immunohistochemistry (IHC) and a negative in-situ hybridization (ISH) testing. Here, ERBB2 is linked to breast cancer.